Back to Search
Start Over
Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report .
- Source :
-
Urology case reports [Urol Case Rep] 2020 Oct 09; Vol. 34, pp. 101444. Date of Electronic Publication: 2020 Oct 09 (Print Publication: 2021). - Publication Year :
- 2020
-
Abstract
- Most common sites of metastasis of urothelial carcinoma (UC) are lungs, liver, lymph nodes and bone. Pembrolizumab, a humanized monoclonal antibody directed against programmed cell death protein-1 (PD-1), represents an effective second-line therapy for advanced UC. Radiotherapy has been shown to induce a mechanism of immunogenic cell death (ICD) resulting in immune memory and advantageous systemic effects. We present the first case of breast metastasis (BM) from a UC described in literature who had an exceptional response to second-line therapy with pembrolizumab in association with radiotherapy, showing the efficacy of combining immunotherapy and radiotherapy even in patients with atypical metastatic sites.<br /> (© 2020 The Authors. Published by Elsevier Inc.)
Details
- Language :
- English
- ISSN :
- 2214-4420
- Volume :
- 34
- Database :
- MEDLINE
- Journal :
- Urology case reports
- Publication Type :
- Report
- Accession number :
- 33088719
- Full Text :
- https://doi.org/10.1016/j.eucr.2020.101444